Treatment of refractory/relapsed Diamond–Blackfan anaemia with eltrombopag
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19357 ↗Kurz gefasst
Klinische Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Brynn B Duncan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Translational Stem Cell Biology Branch, NHLBI, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Anemia, Diamond-Blackfan, Pyrazoles, Hydrazines, Benzoates. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural NIH HHS, Novartis.
Abstract (Originalsprache)
Diamond–Blackfan anaemia (DBA) is a rare, inherited bone marrow failure syndrome with a ribosomal defect causing slowed globin chain production with normal haem synthesis, causing an overabundance of reactive iron/haem and erythroid‐specific cellular toxicity. Eltrombopag, a non‐peptide thrombopoietin receptor agonist, is a potent intracellular iron chelator and induced a robust durable response in an RPS19 ‐mutated DBA patient on another trial. We hypothesized eltrombopag would improve RBC production in DBA patients. We conducted a single‐centre, single‐arm pilot study (NCT04269889) assessing safety and erythroid response of 6 months of daily, fixed‐dose eltrombopag for DBA patients. Fifteen transfusion‐dependent (every 3–5 weeks) patients (median age 18 [range 2–56]) were treated. One responder had sustained haemoglobin improvement and >50% reduction in RBC transfusion frequency. Of note, 7/15 (41%) patients required dose reductions or sustained discontinuation of eltrombopag due to asymptomatic thrombocytosis. Despite the low response rate, eltrombopag has now improved erythropoiesis in several patients with DBA with a favourable safety profile. Dosing restrictions due to thrombocytosis may cause insufficient iron chelation to decrease haem production and improve anaemia in most patients. Future work will focus on erythropoiesis dynamics in patients and use of haem synthesis inhibitors without an impact on other haematopoietic lineages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Stem Cell Biology Branch, NHLBI, Bethesda, Maryland, USA.
- Office of the Clinical Director, NHLBI, Bethesda, Maryland, USA.
- Office of Biostatistics Research, NHLBI, Bethesda, Maryland, USA.
- Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Brynn B Duncan, Colin O Wu, Cynthia E Dunbar, David J Young
Förderung
- Intramural NIH HHS
- Novartis
Zitieren
APA
Duncan, B. B., Lotter, J. L., Superata, J., Barranta, M. E., Machado, T., Darden, I., Venugopal, S., Wu, C. O., Abkowitz, J. L., Dunbar, C. E., & Young, D. J. (2024). Treatment of refractory/relapsed Diamond–Blackfan anaemia with eltrombopag. British Journal of Haematology. https://doi.org/10.1111/bjh.19357
Vancouver
Duncan BB, Lotter JL, Superata J, Barranta ME, Machado T, Darden I, et al. Treatment of refractory/relapsed Diamond–Blackfan anaemia with eltrombopag. British Journal of Haematology. 2024. doi:10.1111/bjh.19357
BibTeX
@article{Duncan2024,
author = {Duncan, Brynn B and Lotter, Jennifer L and Superata, Jeanine and Barranta, Ma Evette and Machado, Tania and Darden, Ivana and Venugopal, Sanjay and Wu, Colin O and Abkowitz, Janis L and Dunbar, Cynthia E and Young, David J},
title = {Treatment of refractory/relapsed Diamond–Blackfan anaemia with eltrombopag},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19357}
}
EUVIMED